Migraine firm wants to eliminate doubt about new product - raises USD 2.8 million for new clinical trial

Medtech company Balancair has raised DKK 19 million (USD 2.8 million) from investors, primarily to finance a clinical trial with over 150 migraine patients from several countries. It hopes that this will eliminate cricitism of the results from the firm's earlier pilot study.

Asger Hee Stjernholm, CEO of migraine company Balancair Photo: BalancAir/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles